ReviewIranian journal of basic medical sciences2025
Innovative strategies and nanocarrier approaches for enhancing the oral bioavailability of macromolecular therapeutics.
Review in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A N-methylated antimicrobial peptide targets the fructose transporter FruA of Staphylococcus aureus.The Journal of antibiotics · 2026Article
- Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review focuses on identifying the primary limitations affecting the oral administration of biologics and evaluates current strategies designed to improve their bioavailability. It also incorporates a bibliometric mapping approach to assess ongoing research trends in this field. A detailed literature survey was performed alongside a bibliometric analysis using VOSviewer to illustrate keyword relationships and the evolution of research activity in oral biologic delivery. Barriers such as enzymatic degradation, restricted epithelial transport, and rapid systemic elimination hinder effective oral delivery of biologics. Innovative approaches including nanocarrier systems, enteric coatings, PEGylation, lipidation, protease inhibitors, and mucoadhesive formulations have been developed to address these issues. Advances like receptor targeted ligand systems and pH sensitive nanocarriers show promise for more efficient absorption. Emerging therapies, including GLP-1 receptor agonists and orally delivered monoclonal antibodies, are highlighted. The review also touches upon therapeutic applications beyond oncology, such as neurodegenerative diseases. Case studies on oral insulin provide valuable clinical development insights. Scaleup production and regulatory challenges are discussed, along with future directions for formulation improvement. Although oral delivery of biologics presents significant obstacles, technological advancements are steadily transforming the landscape. Future research focusing absorption mechanisms and innovative formulation strategies will be crucial for the successful development of effective oral biologic therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.